Biopharma
Biopharma, officially known as Biopharma Limited, is a prominent player in the biopharmaceutical industry, headquartered in Dhaka, Bangladesh. Founded in 1999, the company has established itself as a leader in the development and manufacturing of high-quality generic and innovative medicines, particularly in the fields of oncology, cardiology, and infectious diseases. With a commitment to research and development, Biopharma has achieved significant milestones, including the introduction of several first-to-market products in Bangladesh. Their unique approach combines advanced technology with stringent quality control, ensuring that their offerings meet international standards. Recognised for its contributions to healthcare, Biopharma has positioned itself as a trusted name in the region, serving not only the local market but also expanding its reach across South Asia and beyond.
DitchCarbon Score
How does Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biopharma's score of 30 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biopharma's reported carbon emissions
In 2023, Biopharma reported total carbon emissions of approximately 12.5 million tonnes CO2e, comprising 12.5 million tonnes from Scope 1, 9.2 million tonnes from Scope 2, and 13.1 million tonnes from Scope 3 emissions. The breakdown of Scope 1 emissions includes about 2.4 million tonnes from mobile combustion, 0.8 million tonnes from fugitive emissions, and approximately 9.3 million tonnes from stationary combustion. Scope 2 emissions were primarily from purchased electricity, totalling around 9.2 million tonnes CO2e. In comparison, the 2022 emissions data indicated a total of about 12.6 million tonnes CO2e, with similar distributions across the scopes. Notably, Biopharma has not set specific reduction targets or initiatives as part of their climate commitments, indicating a potential area for future focus in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
|---|---|---|
| Scope 1 | 12,518,000 | 00,000,000 |
| Scope 2 | 7,950,000 | 0,000,000 |
| Scope 3 | 13,069,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
